In a retrospective study, ticagrelor treatment resulted in comparable risk of net adverse clinical events (NACE) compared to clopidogrel treatment among patients from the US and South-Korea with ACS who underwent PCI.
A prespecified subanalysis of ISAR-REACT 5 demonstrated that ticagrelor and prasugrel had comparable efficacy with regard to reducing ischemic events in patients with diabetes, with a similar risk for bleeding.
A post-hoc analysis of the ODYSSEY OUTCOMES trial found that Lp(a) reduction with alirocumab was, independent of LDL-c reduction, associated with reduced total CV events in ACS patients.
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.
Malnutrition, assessed by 3 different scores, was common in a cohort of ACS patients. Malnutrition was associated with increased risk of mortality and MACE, independent of BMI.
This trial in 57 patients with non-STEMI and troponin I ≥5 ng/mL showed that more patients reach LDL-c targets at hospital discharge with evolocumab plus high-intensity statin therapy compared with placebo plus high-intensity statin therapy.
Results from a meta-analysis showed that higher chocolate consumption (>1 time per week or >3.5 times per month) may be beneficial for CAD risk reduction compared to no consumption or <1 time per week.
This analysis of the ODYSSEY OUTCOMES trial showed that alirocumab added to statins significantly reduced CV risk irrespective of age in patients after ACS and was safe in older patients.
ACC 2020 Ticagrelor monotherapy after 3-months DAPT reduces net adverse clinical events compared with continued DAPT in ACS patients who underwent PCI with drug-eluting stents (DES).
ACC 2020 After an initial 3 months of DAPT, ticagrelor monotherapy after complex PCI lowered bleeding without increasing risk of ischemic events compared to continued use of DAPT.
ACC 2020 Prof. Verheugt discusses the results of prespecified analyses of the TWILIGHT trial, in those with diabetes and those with complex PCI (the TWILIGHT-COMPLEX study).
ACC 2020 The TAILOR-PCI trial showed that genotype-guided antiplatelet therapy reduced ischemic events by 34% in patients who underwent PCI compared to conventional therapy.